Back to top
more

ADMA Biologics (ADMA)

(Delayed Data from NSDQ)

$20.29 USD

20.29
4,247,997

+0.72 (3.68%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $20.22 -0.07 (-0.34%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

1-Strong Buy of 5 1        

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin

by Zacks Equity Research

New post hoc analysis of data from Lexicon's (LXRX) phase III study shows improvements in glycemic control when treated with sotagliflozin for type 1 diabetes and chronic kidney disease.

Allogene (ALLO) Inks Deal With Arbor Bio for CRISPR Technology

by Zacks Equity Research

Allogene (ALLO) intends to combine its next generation AlloCAR T platform with Arbor Biotechnologies' proprietary CRISPR gene therapy technology to develop therapies for autoimmune diseases.

Regulus (RGLS) Up 71% on Topline Data from Kidney Disease Study

by Zacks Equity Research

Data from an early-stage study shows that treatment with Regulus' (RGLS) lead drug shows increased biological activity at a higher dose in patients with autosomal dominant polycystic kidney disease.

Pfizer's (PFE) Adcetris Meets Survival Goal in Lymphoma Study

by Zacks Equity Research

Pfizer (PFE) plans to seek approval for the eighth indication for Adcetris based on data from the ECHELON-3 study.

Applied Therapeutics (APLT) Surges 124% in a Month: Here's Why

by Zacks Equity Research

Applied Therapeutics (APLT) surges 124% in a month due to encouraging updates from two separate developmental programs for govorestat to treat different rare neurological indications.

Incyte (INCY) Posts Positive Results on Opzelura From HS Study

by Zacks Equity Research

Incyte's (INCY) Opzelura leads to a significantly greater reduction in abscess and inflammatory nodule (AN) count in HS patients.

Regeneron (REGN) Gets FDA Nod for Praluent Label Extension

by Zacks Equity Research

Regeneron (REGN) obtains FDA approval for Praluent as an adjunct to diet and other LDL-C, lowering therapies to include pediatric patients aged eight and older with HeFH.

Why Moderna (MRNA) Stock Price Was Up 9% on Monday

by Zacks Equity Research

Moderna (MRNA) surges amid initiation reports of a phase II/III study on Merck-partnered experimental cancer therapy to treat patients with cutaneous squamous cell carcinoma, a form of skin cancer.

Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails

by Zacks Equity Research

Acadia (ACAD) tumbles after its late-stage study on pimavanserin to treat negative symptoms of schizophrenia fails to achieve the primary goal with statistical significance.

ASLAN (ASLN) Up 161% on Upbeat Initial Data From Eczema Study

by Zacks Equity Research

ASLAN (ASLN) rises on upbeat initial data from a phase II study of eblasakimab in patients with eczema, who have previously been treated with Dupixent but did not achieve an adequate response.

Amylyx's (AMLX) ALS Drug Fails Pivotal Study, Stock Down 82%

by Zacks Equity Research

Following the study's failure, Amylyx (AMLX) is now uncertain whether to pull its orally administered ALS drug from the market. Management has voluntarily decided to pause all promotions of the drug.

MindMed's (MNMD) Anxiety Drug Gets FDA Breakthrough Therapy Tag

by Zacks Equity Research

The FDA bestows a breakthrough therapy designation to MindMed's (MNMD) MM120 for treating generalized anxiety disorder. Shares rise more than 50% on the news.

Emergent (EBS) Down 16% on Q4 Earnings Miss, Tops on Sales

by Zacks Equity Research

Emergent (EBS) reports mixed earnings for fourth-quarter 2023. The company signs a forbearance agreement with its lenders, effective till April 2023-end.

Creative Medical (CELZ) Up on Orphan Drug Tag for CELZ-101

by Zacks Equity Research

Creative Medical's (CELZ) CELZ-101 gets FDA's Orphan Drug designation for preventing allograft rejection in type-I diabetes patients undergoing pancreatic islet cell transplantation. Stock rises.

Vanda (VNDA) Falls on FDA's CRL to Hetlioz sNDA for Insomnia

by Zacks Equity Research

Vanda's (VNDA) supplemental new drug application seeking approval for Hetlioz to treat insomnia gets a complete response letter from the FDA.

Iterum (ITRM) Plans Early Submission of UTI Drug NDA, Stock Up

by Zacks Equity Research

Iterum (ITRM) stock rises as the company gears up to submit a regulatory application to the FDA seeking approval for oral sulopenem to treat adult women with uUTIs ahead of schedule.

REGENXBIO (RGNX) Soars 15% on Interim Data From DMD Study

by Zacks Equity Research

Data from an early-stage study shows that treatment with REGENXBIO's (RGNX) investigational Duchenne therapy RGX-202 demonstrates early evidence of strength and motor function improvement.

Alnylam (ALNY), Roche's Blood Pressure Drug Meets Study Goal

by Zacks Equity Research

Data from a mid-stage study shows that Alnylam (ALNY) and Roche-partnered zilebesiran, when added to standard-of-care, lowers blood pressure significantly in adults with mild-to-moderate hypertension.

Bayer (BAYRY) Q4 Earnings Top, Crop Science Unit Drives Revenues

by Zacks Equity Research

Bayer (BAYRY) beats earnings estimates in the fourth quarter of 2023, primarily driven by increased sales of Crop Science and Pharmaceuticals products.

Novo Nordisk (NVO) Down Despite Kidney Outcomes Study Success

by Zacks Equity Research

Novo Nordisk (NVO) declines 3% despite achieving the primary endpoint with statistical significance in the FLOW outcomes study evaluating the efficacy of Ozempic 1 mg to treat CKD indication.

Akero (AKRO) Up on Upbeat Week 96 Data From Liver Disease Study

by Zacks Equity Research

Akero (AKRO) reports positive results from its mid-stage study of efruxifermin in pre-cirrhotic metabolic dysfunction-associated steatohepatitis patients at week 96. The stock gains 12%.

Benjamin Rains headshot

Finding Cheap Stocks Under $10 to Buy in March

by Benjamin Rains

Along with the cheap price tags, the stocks we learn how to search for earn strong Zacks Ranks, driven by improving earnings outlooks

FDA Lifts Clinical Hold on Iovance's (IOVA) Lung Cancer Study

by Zacks Equity Research

The FDA removes the clinical hold on Iovance's (IOVA) mid-stage study on LN-145 in certain NSCLC patients after reviewing the company's proposal for additional safety measures and monitoring.

Bayer (BAYRY) Acquires BridgeBio's Cardiovascular Drug

by Zacks Equity Research

Bayer (BAYRY) acquires exclusive marketing rights for cardiovascular drug acoramidis in Europe from BridgeBio for an upfront payment of $310 million.

Adma Biologics (ADMA) Is Up 4.94% in One Week: What You Should Know

by Zacks Equity Research

Does Adma Biologics (ADMA) have what it takes to be a top stock pick for momentum investors? Let's find out.